NASDAQ
ACER

Acer Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Acer Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.8502
Today's High:
$0.903
Open Price:
$0.8611
52W Low:
$1.109
52W High:
$4.56
Prev. Close:
$0.8955
Volume:
266167

Company Statistics

Market Cap.:
$37.29 million
Book Value:
-0.746
Revenue TTM:
$360000
Operating Margin TTM:
-6603.02%
Gross Profit TTM:
$1.26 million
Profit Margin:
0%
Return on Assets TTM:
-62.07%
Return on Equity TTM:
-472.99%

Company Profile

Acer Therapeutics Inc had its IPO on 2017-09-22 under the ticker symbol ACER.

The company operates in the Healthcare sector and Biotechnology industry. Acer Therapeutics Inc has a staff strength of 41 employees.

Stock update

Shares of Acer Therapeutics Inc opened at $0.86 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.85 - $0.9, and closed at $0.87.

This is a -2.36% slip from the previous day's closing price.

A total volume of 266,167 shares were traded at the close of the day’s session.

In the last one week, shares of Acer Therapeutics Inc have slipped by -23.3%.

Acer Therapeutics Inc's Key Ratios

Acer Therapeutics Inc has a market cap of $37.29 million, indicating a price to book ratio of 17.2561 and a price to sales ratio of 174.5231.

In the last 12-months Acer Therapeutics Inc’s revenue was $360000 with a gross profit of $1.26 million and an EBITDA of $-23698394. The EBITDA ratio measures Acer Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Acer Therapeutics Inc’s operating margin was -6603.02% while its return on assets stood at -62.07% with a return of equity of -472.99%.

In Q3, Acer Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Acer Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acer Therapeutics Inc’s profitability.

Acer Therapeutics Inc stock is trading at a EV to sales ratio of 102.7606 and a EV to EBITDA ratio of -1.561. Its price to sales ratio in the trailing 12-months stood at 174.5231.

Acer Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$15.32 million
Total Liabilities
$20.79 million
Operating Cash Flow
$-4905.00
Capital Expenditure
$4905
Dividend Payout Ratio
0%

Acer Therapeutics Inc ended 2024 with $15.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.32 million while shareholder equity stood at $-12207317.00.

Acer Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $20.79 million in other current liabilities, 1637.00 in common stock, $-131362939.00 in retained earnings and $7.65 million in goodwill. Its cash balance stood at $6.38 million and cash and short-term investments were $6.38 million. The company’s total short-term debt was $1,510,571 while long-term debt stood at $6.57 million.

Acer Therapeutics Inc’s total current assets stands at $7.30 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $4.69 million and inventory worth $0.

In 2024, Acer Therapeutics Inc's operating cash flow was $-4905.00 while its capital expenditure stood at $4905.

Comparatively, Acer Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.87
52-Week High
$4.56
52-Week Low
$1.109
Analyst Target Price
$8.5

Acer Therapeutics Inc stock is currently trading at $0.87 per share. It touched a 52-week high of $4.56 and a 52-week low of $4.56. Analysts tracking the stock have a 12-month average target price of $8.5.

Its 50-day moving average was $0.82 and 200-day moving average was $1.4 The short ratio stood at 0.84 indicating a short percent outstanding of 0%.

Around 1838.6% of the company’s stock are held by insiders while 3128.4% are held by institutions.

Frequently Asked Questions About Acer Therapeutics Inc

The stock symbol (also called stock or share ticker) of Acer Therapeutics Inc is ACER

The IPO of Acer Therapeutics Inc took place on 2017-09-22

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
SKF India Ltd (SKFINDIA)
$5269.35
-130.25
-2.41%
SLM Corp (SLM)
$14.16
-0.1
-0.7%
$50.02
-0.4
-0.79%
$10.8
0
0%
$518.25
-32.6
-5.92%
$33.27
-3.69
-9.98%
$16.91
0.04
+0.24%
$71.8
-0.41
-0.57%
$86
-1.56
-1.78%
$34.87
0.55
+1.6%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Address

One Gateway Center, Newton, MA, United States, 02458